Aubagio and Hallucinations - a phase IV clinical study of FDA data

Summary:

Hallucinations is reported as a side effect among people who take Aubagio (teriflunomide), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Ampyra, and have Pain.

The phase IV clinical study analyzes which people have Hallucinations when taking Aubagio. It is created by eHealthMe based on reports of 49,894 people who have side effects when taking Aubagio from the FDA, and is updated regularly.

What is Aubagio?

Aubagio has active ingredients of teriflunomide. It is often used in multiple sclerosis. eHealthMe is studying from 50,041 Aubagio users. Check the latest studies of Aubagio.

What is Hallucinations?

Hallucinations (sensations that appear real but are created by your mind) is found to be associated with 1,893 drugs and 2,728 conditions by eHealthMe. Check the latest studies of Hallucinations.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 08, 2026

49,894 people reported to have side effects when taking Aubagio.
Among them, 58 people (0.12%) have Hallucinations.

Among these 58 people:

How long have people been on Aubagio when they have Hallucinations? *

What is the gender of people who have Hallucinations when taking Aubagio? *

female: 81.25 %
male: 18.75 %

What is the age of people who have Hallucinations when taking Aubagio? *

What are other drugs people take besides Aubagio? *

What are other side effects people have besides Hallucinations? *

Fatigue (feeling of tiredness): 14 people, 24.14%
Memory Loss: 13 people, 22.41%
Headache (pain in head): 12 people, 20.69%
Pain: 12 people, 20.69%
Hair Loss: 11 people, 18.97%
Weakness: 9 people, 15.52%
Fall: 9 people, 15.52%
Rashes (redness): 8 people, 13.79%
Gait Disturbance: 8 people, 13.79%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 8 people, 13.79%

What are the existing conditions these people have? *

Pain: 5 people, 8.62%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 2 people, 3.45%
Vitamin B12 Deficiency: 1 person, 1.72%
Thyroid Diseases: 1 person, 1.72%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 1.72%
Itching: 1 person, 1.72%
Insomnia (sleeplessness): 1 person, 1.72%
Hypoaesthesia (reduced sense of touch or sensation): 1 person, 1.72%
High Blood Cholesterol: 1 person, 1.72%
Hair Loss: 1 person, 1.72%

* Approximation only. Some reports may have incomplete information.

Do you take Aubagio and have Hallucinations?

- Check whether Hallucinations is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aubagio:

Aubagio (50,041 reports)

Hallucinations treatments and more:

Hallucinations (98,683 reports)

Browse all side effects of Aubagio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hallucinations:

Hallucinations (1,893 drugs)

Browse all the conditions that are associated with Hallucinations:

Hallucinations (2,728 conditions)

Related publications that referenced our studies

Ezeji GC, Inoue T, Bahtiyar G, Sacerdote A, "Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism", BMJ case reports, 2015 Feb .
Boschee T, DO PGY II, "Acute Hallucinations: Where Did That Come From?", , 2007 Jan .
Ezeji GC, Inoue T, Bahtiyar G, Sacerdote A, "Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism", BMJ case reports, 2015 Feb .
Boschee T, DO PGY II, "Acute Hallucinations: Where Did That Come From?", , 2007 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on teriflunomide (the active ingredients of Aubagio) and Aubagio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.